Alnylam Pharmaceuticals, Inc. is focused on the discovery, development and commercialization of RNA interference therapeutics. They currently have an approved product, ONPATTRO (patisaran), and multiple pipeline products. The company currently appears to be a good swing trade. Click to read more about my technical analysis and their siRNA technology
Arena Pharmaceuticals, is a company I see value in. The company’s leading pipeline is etrasimod, in which its worldwide Phase 3 trial for the treatment of moderately to severely active ulcerative colitis is currently in the planning process. Click the title of the post to read more.
Zynerba Pharmaceuticals, is a company I see value in. From a technical analysis standpoint, the positive uptrend is an attractive characteristic. Also, with the recent pullback, if ZYNE continues to be supported by the exponential moving average (EMA), it is currently at a “good buy” area. Click the title of the post to read more.
Clinuvel is currently carries high volatility, the positive uptrend is appealing for short-term swing trades. Clinuvel is currently near its previous resistance. From a technical analysis, I don’t believe it is currently in the “good buy” territory. However, if Clinuvel continues to make “higher highs and higher lows,” that break the resistance, Clinuvel might offer a substantial profit. Click the title of the post to read more.
Agios Pharmaceuticals, Inc. is a company I see potential value in. From a technical analysis standpoint, it appears a reversal was confirmed in 2019 and has trended positively. It appears to have met a resistance around $66 and currently found a support near $56. If the support is confirmed, Agios may continue following their positive trend. I have not taken a position; however, this company is currently on my watch list. This company currently has two approved products, TIBSOVO® (ivosidenib) and IDHIFA® (enasidenib), and three other products in clinical development.